{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:29:59Z","timestamp":1778113799937,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,26]]},"DOI":"10.7759\/cureus.26343","type":"journal-article","created":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T15:28:07Z","timestamp":1656257287000},"source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of COVID-19 in Inflammatory Rheumatic Diseases: A Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Thamer Saad","family":"Alhowaish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moustafa S","family":"Alhamadh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman Yousef","family":"Alhabeeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaya Fahad","family":"Aldosari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emad","family":"Masuadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman","family":"Alrashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9540","article-title":"Effect of COVID-19 on the organs","volume":"12","author":"Jain U","year":"2020","unstructured":"Jain U. Effect of COVID-19 on the organs. Cureus. 2020, 12:10.7759\/cureus.9540","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061753","article-title":"COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge","volume":"9","author":"Baj J","year":"2020","unstructured":"Baj J, Karaku\u0142a-Juchnowicz H, Teresi\u0144ski G, et al.. COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med. 2020, 9:10.3390\/jcm9061753","journal-title":"J Clin Med"},{"key":"ref3","unstructured":"Living guidance for clinical management of COVID-19. (2021). https.\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2021-2."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30227-7","article-title":"COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study","volume":"2","author":"Zhong J","year":"2020","unstructured":"Zhong J, Shen G, Yang H, et al.. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol. 2020, 2:557-64. 10.1016\/S2665-9913(20)30227-7","journal-title":"Lancet Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218296","article-title":"Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study","volume":"79","author":"Pablos JL","year":"2020","unstructured":"Pablos JL, Galindo M, Carmona L, et al.. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. 2020, 79:1544-9. 10.1136\/annrheumdis-2020-218296","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00755-x","article-title":"COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations","volume":"18","author":"Grainger R","year":"2022","unstructured":"Grainger R, Kim AH, Conway R, Yazdany J, Robinson PC. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol. 2022, 18:191-204. 10.1038\/s41584-022-00755-x","journal-title":"Nat Rev Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"Ngo ST","year":"2014","unstructured":"Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014, 35:347-69. 10.1016\/j.yfrne.2014.04.004","journal-title":"Front Neuroendocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2011.10.003","article-title":"Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity","volume":"38","author":"Quintero OL","year":"2012","unstructured":"Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, Rojas-Villarraga A, Anaya JM. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun. 2012, 38:109-19. 10.1016\/j.jaut.2011.10.003","journal-title":"J Autoimmun"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218054","article-title":"Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases","volume":"79","author":"Nu\u00f1o L","year":"2020","unstructured":"Nu\u00f1o L, Novella Navarro M, Bonilla G, et al.. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis. 2020, 79:1659-61. 10.1136\/annrheumdis-2020-218054","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2174\/1573397116666201029155105","article-title":"The perfect storm: a rheumatologist's point of view on COVID-19 infection","volume":"17","author":"Kobak S","year":"2021","unstructured":"Kobak S. The perfect storm: a rheumatologist's point of view on COVID-19 infection. Curr Rheumatol Rev. 2021, 17:141-52. 10.2174\/1573397116666201029155105","journal-title":"Curr Rheumatol Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.05.001","article-title":"Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs","volume":"50","author":"Michelena X","year":"2020","unstructured":"Michelena X, Borrell H, L\u00f3pez-Corbeto M, et al.. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020, 50:564-70. 10.1016\/j.semarthrit.2020.05.001","journal-title":"Semin Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04676-4","article-title":"Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes","volume":"40","author":"Montero F","year":"2020","unstructured":"Montero F, Mart\u00ednez-Barrio J, Serrano-Benavente B, et al.. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020, 40:1593-8. 10.1007\/s00296-020-04676-4","journal-title":"Rheumatol Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","author":"Akiyama S","year":"2020","unstructured":"Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020, 10.1136\/annrheumdis-2020-218946","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217888","article-title":"Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US \u2018hot spot\u2019","volume":"79","author":"D\u2019Silva KM","year":"2020","unstructured":"D\u2019Silva KM, Serling-Boyd N, Wallwork R, et al.. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US \u2018hot spot\u2019. Ann Rheum Dis. 2020, 79:1156-62. 10.1136\/annrheumdis-2020-217888","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco M","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, et al.. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020, 79:859-66. 10.1136\/annrheumdis-2020-217871","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson S","year":"2020","unstructured":"Richardson S, Hirsch JS, Narasimhan M, et al.. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020, 323:2052-9. 10.1001\/jama.2020.6775","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020","volume":"69","author":"Garg S","year":"2020","unstructured":"Garg S, Kim L, Whitaker M, et al.. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020. Morb Mortal Wkly Rep. 2020, 69:458-64. 10.15585\/mmwr.mm6915e3","journal-title":"Morb Mortal Wkly Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review","volume":"324","author":"Wiersinga WJ","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020, 324:782-93. 10.1001\/jama.2020.12839","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.05.010","article-title":"COVID-19 in rheumatic disease patients on immunosuppressive agents","volume":"50","author":"Sharmeen S","year":"2020","unstructured":"Sharmeen S, Elghawy A, Zarlasht F, Yao Q. COVID-19 in rheumatic disease patients on immunosuppressive agents. Semin Arthritis Rheum. 2020, 50:680-6. 10.1016\/j.semarthrit.2020.05.010","journal-title":"Semin Arthritis Rheum"},{"key":"ref20","unstructured":"Kingdom of Saudi Arabia - Ministry of Health portal. (2022). https.\/\/www.moh.gov.sa\/en\/Pages\/Default.aspx."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261428","article-title":"Baseline clinical features of COVID-19 patients, delay of hospital admission and clinical outcome: a complex relationship","volume":"17","author":"Dananch\u00e9 C","year":"2022","unstructured":"Dananch\u00e9 C, Elias C, H\u00e9naff L, et al.. Baseline clinical features of COVID-19 patients, delay of hospital admission and clinical outcome: a complex relationship. PLoS One. 2022, 17:10.1371\/journal.pone.0261428","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.26.20219519","article-title":"COVID-19 symptoms at hospital admission vary with age and sex: ISARIC multinational study. [Preprint]","volume":"2020","author":"Pritchard M","year":"2020","unstructured":"Pritchard M. COVID-19 symptoms at hospital admission vary with age and sex: ISARIC multinational study. [Preprint]. medRxiv. 2020, 2020:10.1101\/2020.10.26.20219519","journal-title":"medRxiv"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"Verity R","year":"2020","unstructured":"Verity R, Okell LC, Dorigatti I, et al.. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020, 20:669-77. 10.1016\/S1473-3099(20)30243-7","journal-title":"Lancet Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","volume":"46","author":"Sahraian MA","year":"2020","unstructured":"Sahraian MA, Azimi A, Navardi S, Ala S, Moghadasi AN. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord. 2020, 46:10.1016\/j.msard.2020.102472","journal-title":"Mult Scler Relat Disord"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.562142","article-title":"Rheumatic musculoskeletal diseases and COVID-19 a review of the first 6 months of the pandemic","volume":"7","author":"Stradner MH","year":"2020","unstructured":"Stradner MH, Dejaco C, Zwerina J, Fritsch-Stork RD. Rheumatic musculoskeletal diseases and COVID-19 a review of the first 6 months of the pandemic. Front Med (Lausanne). 2020, 7:10.3389\/fmed.2020.562142","journal-title":"Front Med (Lausanne)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.3342","article-title":"POS1242\u2005factors associated with mortality in patients with rheumatic diseases and COVID-19 in Mexico","volume":"80","author":"Alpizar-Rodriguez D","year":"2021","unstructured":"Alpizar-Rodriguez D, Irazoque-Palazuelos F, Rodriguez-Reyne TS, et al.. POS1242\u2005factors associated with mortality in patients with rheumatic diseases and COVID-19 in Mexico. Ann Rheum Dis. 2021, 80:10.1136\/annrheumdis-2021-eular.3342","journal-title":"Ann Rheum Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16896","article-title":"Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature","volume":"190","author":"Tepasse PR","year":"2020","unstructured":"Tepasse PR, Hafezi W, Lutz M, et al.. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol. 2020, 190:185-8. 10.1111\/bjh.16896","journal-title":"Br J Haematol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217322","article-title":"Are my patients with rheumatic diseases at higher risk of COVID-19?","volume":"79","author":"Figueroa-Parra G","year":"2020","unstructured":"Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza-Delgado DA. Are my patients with rheumatic diseases at higher risk of COVID-19?. Ann Rheum Dis. 2020, 79:839-40. 10.1136\/annrheumdis-2020-217322","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/xcdary","article-title":"COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","volume":"38","author":"Sarzi-Puttini P","year":"2020","unstructured":"Sarzi-Puttini P, Giorgi V, Sirotti S, et al.. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?. Clin Exp Rheumatol. 2020, 38:337-42. 10.55563\/clinexprheumatol\/xcdary","journal-title":"Clin Exp Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26254","article-title":"Microstructure, pathophysiology, and potential therapeutics of COVID-19: a comprehensive review","volume":"93","author":"Singh SP","year":"2021","unstructured":"Singh SP, Pritam M, Pandey B, Yadav TP. Microstructure, pathophysiology, and potential therapeutics of COVID-19: a comprehensive review. J Med Virol. 2021, 93:275-99. 10.1002\/jmv.26254","journal-title":"J Med Virol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.03.047","article-title":"Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection","volume":"526","author":"Luan J","year":"2020","unstructured":"Luan J, Lu Y, Jin X, Zhang L. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun. 2020, 526:165-9. 10.1016\/j.bbrc.2020.03.047","journal-title":"Biochem Biophys Res Commun"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glu197","article-title":"Age-associated increase in cytokine production during systemic inflammation-II: the role of IL-1\u03b2 in age-dependent IL-6 upregulation in adipose tissue","volume":"70","author":"Starr ME","year":"2015","unstructured":"Starr ME, Saito M, Evers BM, Saito H. Age-associated increase in cytokine production during systemic inflammation-II: the role of IL-1\u03b2 in age-dependent IL-6 upregulation in adipose tissue. J Gerontol A Biol Sci Med Sci. 2015, 70:1508-15. 10.1093\/gerona\/glu197","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-4166","article-title":"Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells","volume":"106","author":"Law HK","year":"2005","unstructured":"Law HK, Cheung CY, Ng HY, et al.. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005, 106:2366-74. 10.1182\/blood-2004-10-4166","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25964","article-title":"Tocilizumab for the treatment of severe coronavirus disease 2019","volume":"92","author":"Alattar R","year":"2020","unstructured":"Alattar R, Ibrahim TB, Shaar SH, et al.. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020, 92:2042-9. 10.1002\/jmv.25964","journal-title":"J Med Virol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01844","article-title":"Immunomodulatory drugs in the management of SARS-CoV-2","volume":"11","author":"Burrage DR","year":"2020","unstructured":"Burrage DR, Koushesh S, Sofat N. Immunomodulatory drugs in the management of SARS-CoV-2. Front Immunol. 2020, 11:10.3389\/fimmu.2020.01844","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/101566-outcomes-of-covid-19-in-inflammatory-rheumatic-diseases-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:09Z","timestamp":1707507489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/101566-outcomes-of-covid-19-in-inflammatory-rheumatic-diseases-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,26]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.26343","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,26]]}}}